{"id":11425,"date":"2024-11-05T16:26:11","date_gmt":"2024-11-05T08:26:11","guid":{"rendered":"https:\/\/flcube.com\/?p=11425"},"modified":"2024-11-05T16:26:13","modified_gmt":"2024-11-05T08:26:13","slug":"beijing-mabworks-biotechs-ipo-application-accepted-by-beijing-stock-exchange","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=11425","title":{"rendered":"Beijing Mabworks Biotech’s IPO Application Accepted by Beijing Stock Exchange"},"content":{"rendered":"\n

Beijing Mabworks Biotech Co., Ltd, a China-based biotech firm, has seen its initial public offering (IPO) application of 4,705,150 shares accepted for review by the Beijing Stock Exchange. This marks the first such move by a pre-revenue biotech company following the China Securities Regulatory Commission’s (CSRC) tightening of IPO rules on August 27, 2023. The potential IPO could raise RMB 349 million (USD 49.15 million), which is designated for novel biologic drug research and development (R&D), clinical program investment, and supplementary working capital.<\/p>\n\n\n\n

Mabworks Bio’s Financials and Focus on Innovative Antibody Drugs<\/strong>
Mabworks Bio, which concentrates on the R&D and industrialization of innovative antibody targeted drugs, reported revenues of only RMB 1.46 million for the first half of 2024, alongside a net loss of RMB 126 million. The company’s lead program, MIL62, an in-house developed third-generation CD20-targeted monoclonal antibody (mAb), has received a breakthrough therapy designation (BTD) from the National Medical Products Administration (NMPA) for the treatment of primary membranous nephropathy (PMN). Other programs under development include MBS303\/MSC303 and MBS314.<\/p>\n\n\n\n

Partnerships and Industry Collaborations<\/strong>
Mabworks Bio is partnered with several high-profile Chinese companies, including Zhejiang Hisun Pharmaceutical Co., Ltd (SHA: 600267<\/a>), Livzon Pharmaceutical Group Inc. (HKG: 1513<\/a>), and Betta Pharmaceuticals Co., Ltd (SHE: 300558<\/a>), among others, indicating its strategic industry collaborations.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Beijing Mabworks Biotech Co., Ltd, a China-based biotech firm, has seen its initial public offering…<\/p>\n","protected":false},"author":1,"featured_media":11427,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[231,766,1228,72,457,1938,1466,1030],"class_list":["post-11425","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-betta-pharmaceuticals","tag-hisun-pharmaceutical","tag-hkg-1513","tag-ipo","tag-livzon-pharmaceutical","tag-mabworks-biotech","tag-sha-600267","tag-she-300558"],"yoast_head":"\nBeijing Mabworks Biotech's IPO Application Accepted by Beijing Stock Exchange - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Beijing Mabworks Biotech Co., Ltd, a China-based biotech firm, has seen its initial public offering (IPO) application of 4,705,150 shares accepted for review by the Beijing Stock Exchange. This marks the first such move by a pre-revenue biotech company following the China Securities Regulatory Commission's (CSRC) tightening of IPO rules on August 27, 2023. The potential IPO could raise RMB 349 million (USD 49.15 million), which is designated for novel biologic drug research and development (R&D), clinical program investment, and supplementary working capital.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=11425\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Beijing Mabworks Biotech's IPO Application Accepted by Beijing Stock Exchange\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=11425\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-05T08:26:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-05T08:26:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/a4d2fc6a135bc81f6c8e04bad156e0a2.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1923\" \/>\n\t<meta property=\"og:image:height\" content=\"1280\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11425#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11425\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Beijing Mabworks Biotech’s IPO Application Accepted by Beijing Stock Exchange\",\"datePublished\":\"2024-11-05T08:26:11+00:00\",\"dateModified\":\"2024-11-05T08:26:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11425\"},\"wordCount\":223,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11425#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/a4d2fc6a135bc81f6c8e04bad156e0a2.jpeg\",\"keywords\":[\"Betta Pharmaceuticals\",\"Hisun Pharmaceutical\",\"HKG: 1513\",\"IPO\",\"Livzon Pharmaceutical\",\"Mabworks Biotech\",\"SHA: 600267\",\"SHE: 300558\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=11425#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11425\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=11425\",\"name\":\"Beijing Mabworks Biotech's IPO Application Accepted by Beijing Stock Exchange - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11425#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11425#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/a4d2fc6a135bc81f6c8e04bad156e0a2.jpeg\",\"datePublished\":\"2024-11-05T08:26:11+00:00\",\"dateModified\":\"2024-11-05T08:26:13+00:00\",\"description\":\"Beijing Mabworks Biotech Co., Ltd, a China-based biotech firm, has seen its initial public offering (IPO) application of 4,705,150 shares accepted for review by the Beijing Stock Exchange. This marks the first such move by a pre-revenue biotech company following the China Securities Regulatory Commission's (CSRC) tightening of IPO rules on August 27, 2023. The potential IPO could raise RMB 349 million (USD 49.15 million), which is designated for novel biologic drug research and development (R&D), clinical program investment, and supplementary working capital.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11425#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=11425\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11425#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/a4d2fc6a135bc81f6c8e04bad156e0a2.jpeg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/a4d2fc6a135bc81f6c8e04bad156e0a2.jpeg\",\"width\":1923,\"height\":1280,\"caption\":\"Beijing Mabworks Biotech's IPO Application Accepted by Beijing Stock Exchange\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11425#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Beijing Mabworks Biotech’s IPO Application Accepted by Beijing Stock Exchange\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Beijing Mabworks Biotech's IPO Application Accepted by Beijing Stock Exchange - Insight, China's Pharmaceutical Industry","description":"Beijing Mabworks Biotech Co., Ltd, a China-based biotech firm, has seen its initial public offering (IPO) application of 4,705,150 shares accepted for review by the Beijing Stock Exchange. This marks the first such move by a pre-revenue biotech company following the China Securities Regulatory Commission's (CSRC) tightening of IPO rules on August 27, 2023. The potential IPO could raise RMB 349 million (USD 49.15 million), which is designated for novel biologic drug research and development (R&D), clinical program investment, and supplementary working capital.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=11425","og_locale":"en_US","og_type":"article","og_title":"Beijing Mabworks Biotech's IPO Application Accepted by Beijing Stock Exchange","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=11425","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-11-05T08:26:11+00:00","article_modified_time":"2024-11-05T08:26:13+00:00","og_image":[{"width":1923,"height":1280,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/a4d2fc6a135bc81f6c8e04bad156e0a2.jpeg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=11425#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=11425"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Beijing Mabworks Biotech’s IPO Application Accepted by Beijing Stock Exchange","datePublished":"2024-11-05T08:26:11+00:00","dateModified":"2024-11-05T08:26:13+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=11425"},"wordCount":223,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=11425#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/a4d2fc6a135bc81f6c8e04bad156e0a2.jpeg","keywords":["Betta Pharmaceuticals","Hisun Pharmaceutical","HKG: 1513","IPO","Livzon Pharmaceutical","Mabworks Biotech","SHA: 600267","SHE: 300558"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=11425#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=11425","url":"https:\/\/flcube.com\/?p=11425","name":"Beijing Mabworks Biotech's IPO Application Accepted by Beijing Stock Exchange - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=11425#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=11425#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/a4d2fc6a135bc81f6c8e04bad156e0a2.jpeg","datePublished":"2024-11-05T08:26:11+00:00","dateModified":"2024-11-05T08:26:13+00:00","description":"Beijing Mabworks Biotech Co., Ltd, a China-based biotech firm, has seen its initial public offering (IPO) application of 4,705,150 shares accepted for review by the Beijing Stock Exchange. This marks the first such move by a pre-revenue biotech company following the China Securities Regulatory Commission's (CSRC) tightening of IPO rules on August 27, 2023. The potential IPO could raise RMB 349 million (USD 49.15 million), which is designated for novel biologic drug research and development (R&D), clinical program investment, and supplementary working capital.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=11425#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=11425"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=11425#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/a4d2fc6a135bc81f6c8e04bad156e0a2.jpeg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/a4d2fc6a135bc81f6c8e04bad156e0a2.jpeg","width":1923,"height":1280,"caption":"Beijing Mabworks Biotech's IPO Application Accepted by Beijing Stock Exchange"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=11425#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Beijing Mabworks Biotech’s IPO Application Accepted by Beijing Stock Exchange"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/a4d2fc6a135bc81f6c8e04bad156e0a2.jpeg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11425","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11425"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11425\/revisions"}],"predecessor-version":[{"id":11428,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11425\/revisions\/11428"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/11427"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11425"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=11425"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=11425"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}